The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Sequential or up-front triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma (HCC): MONTBLANC.
 
Enrico N. De Toni
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Lilly; Pfizer; Roche; TERUMO
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Lilly; Pfizer; Roche; TERUMO
Research Funding - AstraZeneca; Bayer; Bristol-Myer Squibb; Ipsen; Lilly; Roche
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Bristol-Myers Squibb; Celsion; IPSEN; Roche
 
Julia Mayerle
No Relationships to Disclose
 
Bettina Oehrle
No Relationships to Disclose
 
Max Seidensticker
Stock and Other Ownership Interests - AstraZeneca; Novartis; Roche
Honoraria - AstraZeneca; Bayer; Cook Medical; Siemens Healthineers; SIRTEX Medical
Research Funding - SIRTEX Medical (Inst)
 
Lorenza Rimassa
Honoraria - Abbvie; Amgen; AstraZeneca; AstraZeneca; Bayer; Bristol-Myers Squibb Italy; Eisai; Gilead Sciences; Incyte; Ipsen; Lilly; Merck Serono; Roche; Sanofi; SERVIER
Consulting or Advisory Role - Amgen; ArQule; AstraZeneca; Basilea; Baxter; Bayer; Bristol-Myers Squibb; Celgene; Eisai; Elevar Therapeutics; Exelixis; Genenta Science; Hengrui Therapeutics; Incyte; Ipsen; IQvia; Italfarmaco; Jazz Pharmaceuticals; Lilly; Merck Sharp & Dohme; Nerviano Medical Sciences; Roche; Sanofi; SERVIER; Sirtex Medical; Taiho Oncology; Zymeworks
Research Funding - Agios (Inst); ARMO BioSciences (Inst); ArQule (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Eisai (Inst); Exelixis (Inst); Exelixis/Ipsen (Inst); FibroGen (Inst); Incyte (Inst); Ipsen (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Nerviano Medical Sciences (Inst); Roche; Zymeworks (Inst)
Travel, Accommodations, Expenses - ArQule; AstraZeneca; Ipsen
 
Ursula Ehmer
Honoraria - AstraZeneca; Falk Pharma
Consulting or Advisory Role - AstraZeneca; Bayer; Eisai
Research Funding - AstraZeneca; Eisai; Ipsen; MSD; Roche
Travel, Accommodations, Expenses - Biotest
 
Andreas Geier
Consulting or Advisory Role - Abbvie; Alexion Pharmaceuticals; Bayer; Bristol-Myers Squibb; Eisai; Gilead Sciences; Intercept Pharmaceuticals; Ipsen; MSD; Novartis; Pfizer; Roche; Sanofi Aventis GmbH
 
Florian P Reiter
Honoraria - Abbvie; AstraZeneca; Falk Foundation; Gilead Sciences; Ipsen; Novartis
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Falk Foundation; Gilead Sciences; Ipsen; Novartis
 
Thomas Jens Ettrich
Consulting or Advisory Role - AstraZeneca; Bayer; BMS GmbH & Co. KG; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Eisai; Incyte; Ipsen; Lilly; Merck Serono; MSD; Pierre Fabre; Roche; Sanofi; SERVIER
Research Funding - Baxalta/Shire
Travel, Accommodations, Expenses - Ipsen
 
Alexander B Philipp
Honoraria - Falk Foundation
Travel, Accommodations, Expenses - Roche Pharma AG
 
Daniel Christoph Rössler
Honoraria - Bayer; Ipsen
Consulting or Advisory Role - Bayer
Travel, Accommodations, Expenses - Ipsen
 
Najib Ben Khaled
Honoraria - AstraZeneca; Falk Foundation